Active	Status	Sponsor type	Region	Phase	Filter
7 Active 0 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bird, w
adored, NCT05003804: Allergic Disease Onset Prevention Study	Active, not recruiting	1/2	264	US, RoW	STMC-103H, Placebo	Siolta Therapeutics, Inc.	Atopic Dermatitis, Type 1 Hypersensitivity	11/24	10/25
Hedrick, Carolyn
ARGUS, NCT04462770 / 2021-003425-30: A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome	Recruiting	3	150	Europe, Canada, US, RoW	Clemizole HCl, EPX-100, Placebo	Epygenix, Harmony Biosciences Management, Inc.	Dravet Syndrome	04/26	05/29
RISE 2, NCT06132893: A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy	Recruiting	2/3	390	Europe, US, RoW	BHV-7000, Placebo	Biohaven Therapeutics Ltd.	Focal Epilepsy	08/25	09/25
NCT04873869 / 2020-003140-83: Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)	Active, not recruiting	2	52	US	NBI-921352, Placebo	Neurocrine Biosciences	SCN8A Developmental and Epileptic Encephalopathy Syndrome	12/25	12/25
MTLE, NCT05135091: FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy	Recruiting	1/2	58	US	NRTX-1001, GABA-secreting interneurons, Sham Comparator	Neurona Therapeutics, California Institute for Regenerative Medicine (CIRM)	Mesial Temporal Lobe Epilepsy	02/28	02/42

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bird, w
adored, NCT05003804: Allergic Disease Onset Prevention Study	Active, not recruiting	1/2	264	US, RoW	STMC-103H, Placebo	Siolta Therapeutics, Inc.	Atopic Dermatitis, Type 1 Hypersensitivity	11/24	10/25
Hedrick, Carolyn
ARGUS, NCT04462770 / 2021-003425-30: A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome	Recruiting	3	150	Europe, Canada, US, RoW	Clemizole HCl, EPX-100, Placebo	Epygenix, Harmony Biosciences Management, Inc.	Dravet Syndrome	04/26	05/29
RISE 2, NCT06132893: A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy	Recruiting	2/3	390	Europe, US, RoW	BHV-7000, Placebo	Biohaven Therapeutics Ltd.	Focal Epilepsy	08/25	09/25
NCT04873869 / 2020-003140-83: Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)	Active, not recruiting	2	52	US	NBI-921352, Placebo	Neurocrine Biosciences	SCN8A Developmental and Epileptic Encephalopathy Syndrome	12/25	12/25
MTLE, NCT05135091: FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy	Recruiting	1/2	58	US	NRTX-1001, GABA-secreting interneurons, Sham Comparator	Neurona Therapeutics, California Institute for Regenerative Medicine (CIRM)	Mesial Temporal Lobe Epilepsy	02/28	02/42